News
The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...
Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback